Zenas BioPharma, Inc.

ZBIO

NASDAQ

Healthcare

Biotechnology

Waltham, MA, US130 employeeszenasbio.com

$21.48

+1.12(5.50%)

Mkt Cap $959M

$6.77

$43.17

52-Week Range

At a Glance

AI-generated

Zenas BioPharma, Inc.

Revenue breakdown: Single Reportable Segment (100%).

8-K

Zenas BioPharma completed a $200 million convertible notes offering and a $100 million equity offering on March 31, 2026, to fund its clinical pipeline and potential commercial launch.

$959M

Market Cap

$10M

Revenue

-$363M

Net Income

Employees130

Fundamentals

How The Business Makes Money

Revenue by Segment

Single Reportable Segment100%($15M)

Activity

What Changed Recently

Management Change

Feb 12, 2026

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February

Material Agreement

Mar 30, 2026

| Entry into a Material Definitive Agreement | |---|---| On March 31, 2026, Zenas BioPharma, Inc. (the “Company”) completed its public offering (the “Convertibl

Financial Results

Mar 15, 2026

Results of Operations and Financial Condition. On March 16, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter

Financial Results+3 More

Jan 4, 2026

. Results of Operations and Financial Condition Zenas BioPharma, Inc. (the “Company”) reports that it had a preliminary unaudited amount of cash, cash equivalen

Peer Companies

Company	Price	Change	Market Cap	P/E
RLAYRelay Therapeutics, Inc.	$12.56	+16.67%	$2.2B	-6.1
SNDXSyndax Pharmaceuticals, I...	$25.08	+5.04%	$2.2B	-7.3
NTLAIntellia Therapeutics, In...	$13.13	-1.09%	$1.6B	-3.4
TRVITrevi Therapeutics, Inc.	$11.93	+3.02%	$1.5B	-36.6
WVEWave Life Sciences Ltd.	$7.25	+6.08%	$1.4B	-10.2
NVAXNovavax, Inc.	$7.71	-3.93%	$1.3B	3.6
AMLXAmylyx Pharmaceuticals, I...	$15.02	+4.66%	$1.2B	-8.8
INBXInhibrx Biosciences, Inc.	$63.59	-5.17%	$929M	-7.1

Analyst View

Company Profile

CIK0001953926

ISINUS98937L1052

CUSIP98937L105

Phone(857) 271-2954

AddressNorth Building, Waltham, MA, 02451, US

SEC EDGAR